Jun. 19 at 7:55 PM
$SRRK trades at the highest multiple of analyst consensus revenue estimates of the 6 bios noted on the attachment with active PDUFA dates. This is not investment advice. We're only sharing an observation around SRRK's high multiple versus the 5 peers. Can anyone pushback?
$MLYS just closed an equity financing not 3 weeks ago at
$26.50 per share.
$VRDN trades at the lowest multiple. We do not follow VRDN in any detail but we understand VRDN owes DRI Healthcare a 7.5% royalty on all Elogrobart sales. Even though we read Amgen's Tepezza is better in TED, investors closed a
$350MM convertible debt offering after the data was published so WTF do we know.
$VERA closed a financing last December at
$42.50/share last December. We read analysts project Atacicept peak sales of
$1.2 to
$2.2B. VERA appears to be the best value of the 6 just based on multiples.
$PRAX 52-week high was
$366/share before reporting its Vormatrigine data earlier this month.
Again we'd genuinely like to understand SRRK
